Show simple item record

dc.creatorBuzharevski, Antonio
dc.creatorPaskas, Svetlana
dc.creatorSárosi, Menyhárt‐Botond
dc.creatorLaube, Markus
dc.creatorLönnecke, Peter
dc.creatorNeumann, Wilma
dc.creatorMijatović, Sanja
dc.creatorMaksimović-Ivanić, Danijela
dc.creatorPietzsch, Jens
dc.creatorHey-Hawkins, Evamarie
dc.date.accessioned2019-02-07T09:46:27Z
dc.date.available2900-01-01
dc.date.issued2019
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.201800685
dc.identifier.urihttps://ibiss-r.rcub.bg.ac.rs/handle/123456789/3254
dc.description.abstractNonsteroidal anti-inflammatory drugs (NSAIDs) are the most common way of treating inflammatory disorders. Their widespread use helped reveal their other modes of action as pharmaceuticals, such as a profound effect on various cancers. Celecoxib has proven to be a very prominent member of this group with cytostatic activities. On the other hand, the highly dynamic field of drug design is constantly searching for new ways of modifying known structures to obtain more powerful and less harmful drugs. A very interesting development is the implementation of carboranes in pharmacologically active structures, mostly as phenyl mimetics. Herein we report the synthesis of three carborane-containing derivatives of the COX-2-selective NSAID celecoxib. The new compounds proved to have promising cytostatic potential against various melanoma and colorectal adenocarcinoma cell lines. Inhibited proliferation accompanied by caspase-independent apoptotic cell death was found to be the main cause of decreased cell viability upon treatment with the most efficient celecoxib analogue, 3 b (4-[5-(1,7-dicarba-closo-dodecaboranyl)-3-trifluoromethyl-1H-pyrazol-1-yl]-1-methylsulfonylbenzene).
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173013/RS//
dc.relationDeutscher Akademischer Austauschdienst
dc.relationDeutsche Forschungsgemeinschaft. Grant Numbers: He 1376/38-1, SA 2902/2-1
dc.rightsrestrictedAccess
dc.sourceChemMedChem
dc.subjectCancer
dc.subjectCarboranes
dc.subjectCelecoxib
dc.subjectCytotoxicity
dc.subjectDrug discovery
dc.titleCarboranyl Analogues of Celecoxib with Potent Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines.
dc.typearticleen
dc.rights.licenseARR
dcterms.abstractМаксимовић-Иванић, Данијела; Пиетзсцх, Јенс; Лöннецке, Петер; Хеy-Хаwкинс, Евамарие; Бузхаревски, Aнтонио; Паскас, Светлана; Сáроси, Менyхáрт‐Ботонд; Лаубе, Маркус; Неуманн, Wилма; Мијатовић, Сања;
dc.rights.holder© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
dc.citation.issue3
dc.citation.volume14
dc.identifier.doi10.1002/cmdc.201800685
dc.identifier.pmid30602073
dc.identifier.scopus2-s2.0-85060592983
dc.identifier.wos000458432600004
dc.citation.apaBuzharevski, A., Paskas, S., Sárosi, M., Laube, M., Lönnecke, P., Neumann, W., … Hey-Hawkins, E. (2019). Carboranyl Analogues of Celecoxib with Potent Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines. ChemMedChem, 14(3), 315–321.
dc.citation.vancouverBuzharevski A, Paskas S, Sárosi M, Laube M, Lönnecke P, Neumann W, Mijatovic S, Maksimovic-Ivanic D, Pietzsch J, Hey-Hawkins E. Carboranyl Analogues of Celecoxib with Potent Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines. ChemMedChem. 2019;14(3):315–21.
dc.citation.spage315
dc.citation.epage321
dc.type.versionpublishedVersionen
dc.citation.rankM21


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record